Using ULT to Achieve Target Serum Urate Levels Linked to Lower Fracture Risk in Gout
Researchers evaluated effect of lowering serum urate levels to a target level on fracture risk among patients with gout.
All articles by Jessica Nye, PhD
Colchicine Use in Gout Not Associated With Higher Cardiovascular Event Risk
Researchers studied the effect of colchicine on cardiovascular outcomes among patients with gout with and without coronary artery disease.
Could Mean Platelet Volume Serve as a Prognostic Indicator for Outcomes in Cancer?
Researchers sought to determine the predictive value of mean platelet volume as a marker for cancer outcomes.
Camonsertib-PARP Inhibitor Combos May Meet Unmet Need in Advanced Solid Tumors
Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests.
ALLO-316, a CAR T-Cell Therapy, Shows Activity in Advanced RCC
ALLO-316 has shown activity in a phase 1 study of patients with heavily pretreated, advanced clear cell renal cell carcinoma.
MMAI Model More Accurately Predicts Outcomes of High-Risk Prostate Cancer
An MMAI model can accurately predict long-term outcomes in patients with high-risk prostate cancer, a study suggests.
New Model Better Predicts Relapse in Stage I Seminoma
A new risk stratification model can identify patients with stage I seminoma who have a high risk of relapse, according to researchers.
Cabozantinib Shows Activity in Advanced RCC After CPI-Based Combinations
Cabozantinib can produce responses in patients with advanced clear cell RCC whose disease progressed on first-line checkpoint inhibitor-based therapy, a phase 2 study suggests.
Sacituzumab Govitecan Elicits Responses in Platinum-Ineligible Metastatic Urothelial Carcinoma
Sacituzumab govitecan has demonstrated activity in patients with platinum-ineligible metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy.
TALAPRO-2: Talazoparib Improves rPFS in Metastatic Castration-Resistant Prostate Cancer
Adding talazoparib to first-line treatment with enzalutamide improves radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer, results of the TALAPRO-2 trial suggest.
- Loading...
Loading...
Next post in Genitourinary Cancers Symposium
Loading... 
Loading...